Anaemia associated with androgen deprivation in patients with prostate cancer receiving combined hormone blockade

British Journal of Urology

Volumn 79, Issue 6, 1997, Pages 933-941

  Strum, S B ^a,b   McDermed, J E ^a   Scholz, M C ^a   Johnson, H ^a   Tisman, G ^a  

^a Centinela Freeman Regional Medical Center   (United States)

^b The Institute for Prostate Cancer Research   (United States)

Author keywords

Anaemia; Androgen deprivation; Combined hormone blockade; Haemoglobin; Prostate cancer

Indexed keywords

ANDROGEN; ANTIANDROGEN; FINASTERIDE; FLUTAMIDE; GONADORELIN AGONIST; HEMOGLOBIN; LEUPRORELIN; RECOMBINANT ERYTHROPOIETIN; TESTOSTERONE;

ADULT; AGED; ANEMIA; ARTICLE; CLINICAL TRIAL; HEMOGLOBIN DETERMINATION; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE CANCER;

EID: 0031400347     PISSN: 00071331     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1464-410x.1997.00234.x     Document Type: Article

References (21)

1. Beck JR, Kattan MV, Miles BJ. A critique of the decision analysis for clinically localized prostate cancer. J Urol 1994; 152: 1894-9
2. Labrie F, Dupont A, Belanger A et al. Combination therapy with flutamide and castration (LHRH agonist or orchiectomy) in advanced prostate cancer: a marked improvement in response and survival. J Steroid Biochem 1985; 123: 833-41
3. Crawford ED, Blumenstein BA, Goodman PJ et al. Leuprolide with and without flutamide in advanced prostate cancer. Cancer 1990; 66 (Suppl 1): 1039-44
4. Eisenberger M, Crawford ED, McLeod D et al. A comparison of leuprolide and flutamide vs leuprolide alone in newly diagnosed stage D2 prostate cancer: Prognostic and therapeutic importance of the minimal disease subset. Proc Am Soc Clin Oncol 1992; 11: 201 (abstract)
5. Strum SB, Scholz MC, Strum M. Prolonged non-detectable PSA (NDPSA) in PC patients treated with androgen deprivation may allow for discontinuation of hormone blockade (CHB). International Symposium on Recent Advances in Diagnosis and Treatment of Prostate Cancer, Quebec City, September 21-23, 1995 (poster)
6. Higano CS, Ellis WJ, Lange PH. Intermittent androgen suppression for treatment of prostate cancer: the Seattle pilot experience. Proc Am Soc Clin Oncol 1996; 15: 243 (abstract)
7. Labrie F, Dupont A, Gomez J et al. Downstaging of localized prostate cancer by neoadjuvant therapy with flutamide and lupron: the first controlled and randomized trial. Clin Invest Med 1993; 16: 499-509
8. Kocheril PG, Shamsa F, Forman JD. The significance and pattern of change of PSA in patients treated with neoadjuvant hormonal therapy and radiotherapy. Proc Am Soc Clin Oncol 1996; 15: 243 (abstract)
9. Hamilton JB. The role of testosterone secretion as indicated by the effects of castration in man and by studies of pathological conditions and the short lifespan associated with maleness. Recent Prog Horm Res 1948; 3: 257-89
10. Weber JP, Walsh PC, Peters CA, Spivak JL. Effect of reversible androgen deprivation on hemoglobin and serum immunoreactive erythropoietin in men. Am J Hemat 1991; 36: 190-4
11. Eri LM, Tveter KJ. Safety, side effects and patient acceptance of the luteinizing hormone releasing hormone agonist leuprolide in the treatment of benign prostatic hyperplasia. J Urol 1994; 152: 448-52
12. Strum SB, Tisman G. Anemia of androgen deprivation (AAD) in patients receiving combination hormonal blockade: response to erythropoietin. Presented at the 6th International Symposium on Supportive Care in Cancer, Abstract 0-1, New Orleans. LA, March 2-5, 1994
13. Strum SB, Tisman G. Anemia of androgen deprivation (AAD) in patients receiving combination hormone blockade: response to erythropoietin. Proc Am Soc Clin Oncol 1994; 13: 238
14. Asbell SO, Tester WJ. The incidence of anemia in prostate cancer patients treated with androgen suppression and pelvic radiotherapy. Proc Am Soc Clin Oncol 1994; 13: 241 (abstract)
15. Sogani PC, Vagaiwala MR, Whitmore WF. Experience with flutamide in patients with advanced prostate cancer without prior hormone therapy. Cancer 1984; 54: 744-50
16. Prout GR, Keating MA, Griffin PP et al. Long-term experience with flutamide in patients with prostatic carcinoma. Urology 1989; 34 (Suppl 4): 37-45
17. Chang A, Yeap B, Davis T et al. Double-blind, randomized study of primary hormonal treatment of Stage D2 prostate carcinoma: flutamide versus diethylstilbestrol. J Clin Oncol 1996; 14: 2250-7
18. Kuhn JM, Billebaud T, Navratil H et al. Prevention of the transient adverse effect of a gonadotropin releasing hormone analog (Buserelin) in metastatic carcinoma by administration of an antiandrogen (Nilutamide). N Engl J Med 1989; 321: 413-8
19. Fleshner NE, Trachenberg J. Treatment of advanced prostate cancer with the combination of finasteride plus flutamide: Early results. Eur Urol 1993; 24 (Suppl 2): 106-12
20. Shamdas GJ, Ahman FR, Matzer MB, Ritchie JM. Leukoerythroblastic anemia in metastatic prostate cancer. Clinical and prognostic significance in patients with hormone-refractory disease. Cancer 1993; 71: 3594-600
21. Modder B, Foley JE, Fisher JW. The in vitro and in vivo effects of testosterone and steroid metabolites on erythroid colony forming cells (CFU-E). J Pharmacol Exp Ther 1978; 207: 1004-12